Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genor Biopharma Holdings Limited ( (HK:6998) ) has shared an announcement.
Genor Biopharma Holdings Limited announced that all resolutions proposed at its extraordinary general meeting on 22 December 2025 were duly passed by poll, including approval of a merger agreement dated 13 September 2024 with a target company and the related issuance of consideration shares under a specific mandate. Shareholders also approved the grant of a whitewash waiver, consent to a special deal and an increase in the company’s authorised share capital, measures that collectively facilitate the proposed merger and potential new listing, and position the company for larger-scale equity financing and strategic expansion, with directors authorised to execute all necessary documents and actions to implement these transactions.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a Hong Kong-listed biopharmaceutical company focused on the research, development and commercialisation of innovative biologic drugs. The company operates in the healthcare and life sciences sector, leveraging capital markets to support its pipeline development and strategic transactions aimed at expanding its product portfolio and market presence.
YTD Price Performance: 96.53%
Average Trading Volume: 860,208
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.79B
For a thorough assessment of 6998 stock, go to TipRanks’ Stock Analysis page.